1 of 1
Story summary
- Researchers found type-2 diabetes patients who began GLP-1 receptor agonists had a 21% lower three-year fragility-fracture risk than new DPP-4 inhibitor users.
- The biggest reductions were for hip and femur fractures, which can be fatal within a year for up to one-third of patients.
- Christopher D. Hamad, MD, said the observational study cannot prove causation.
- David Cutler, MD, warned the lower risk may reflect other factors and mechanisms remain untested.
